Literature DB >> 16206149

A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer.

Wilson Z Shou1, Lisa Magis, Austin C Li, Weng Naidong, Matthew S Bryant.   

Abstract

In vitro metabolic stability experiments using microsomes or other liver preparations are important components in the discovery and lead-optimization stages of compound selection in the pharmaceutical industry. Currently, liquid chromatography-tandem mass spectrometric (LC-MS/MS) support of in vitro metabolic stability studies primarily involves the monitoring of disappearance of parent compounds, using selected reaction monitoring (SRM) on triple-quadrupole instruments. If moderate to high turnover is observed, separate metabolite identification experiments are then conducted to characterize the biotransformation products. In this paper, we present a novel method to simultaneously perform metabolite screening in addition to the quantitative stability measurements, both within the same chromatographic run. This is accomplished by combining SRM and SRM-triggered, information-dependent acquisition (IDA) of MS/MS spectra on a hybrid triple-quadrupole linear ion trap (QqQLIT) mass spectrometer. Microsomal stability experiments using model compounds, bufuralol, propranolol, imipramine, midazolam, verapamil and diclofenac, were used to demonstrate the applicability of our approach. This SRM + SRM-IDA approach generated metabolic stability results similar to those obtained by conventional SRM-only approach. In addition, MS/MS spectra from potential metabolites were obtained with the enhanced product ion (EPI) scan function of LIT during the same injection. These spectra were correlated to the spectra of parent compounds to confirm the postulated structures. The time-concentration profiles of identified metabolites were also estimated from the acquired data. This approach has been successfully used to support discovery programs. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206149     DOI: 10.1002/jms.917

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  6 in total

1.  Metabolite profiling of praziquantel and its analogs during the analysis of in vitro metabolic stability using information-dependent acquisition on a hybrid triple quadrupole linear ion trap mass spectrometer.

Authors:  Jiangeng Huang; Sai Praneeth R Bathena; Yazen Alnouti
Journal:  Drug Metab Pharmacokinet       Date:  2010-09-22       Impact factor: 3.614

2.  Driving efficiency in a high-throughput metabolic stability assay through a generic high-resolution accurate mass method and automated data mining.

Authors:  Wenqing Shui; Song Lin; Allen Zhang; Yan Chen; Yingying Huang; Mark Sanders
Journal:  Protein Cell       Date:  2011-09-09       Impact factor: 14.870

3.  The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.

Authors:  Ji-Yoon Lee; Sang Kyum Kim; Kiho Lee; Soo Jin Oh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.

Authors:  Alene T McCoy; Caroline C Benoist; John W Wright; Leen H Kawas; Jyote M Bule-Ghogare; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

5.  Comparison of trapping profiles between d-peptides and glutathione in the identification of reactive metabolites.

Authors:  Jaana E Laine; Merja R Häkkinen; Seppo Auriola; Risto O Juvonen; Markku Pasanen
Journal:  Toxicol Rep       Date:  2015-07-09

6.  Metabolite Profiling and Characterization of LW6, a Novel HIF-1α Inhibitor, as an Antitumor Drug Candidate in Mice.

Authors:  Kiho Lee; Ji-Yoon Lee; Kyeong Lee; Cho-Rock Jung; Min Ju Kim; Jung Ah Kim; Dong Gu Yoo; Eun Jin Shin; Soo Jin Oh
Journal:  Molecules       Date:  2021-03-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.